Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Skye Bioscience, Inc. , a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through modulation of the CB1 receptor, to address diseases including glaucoma and...
Source: marketscreener.com